527 related articles for article (PubMed ID: 30244487)
1. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
2. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
Kosche C; Owen JL; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
[TBL] [Abstract][Full Text] [Related]
3. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
4. Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report.
Fietz S; Fröhlich A; Mauch C; de Vos-Hillebrand L; Fetter T; Landsberg J; Hoffmann F; Sirokay J
Front Immunol; 2023; 14():1324231. PubMed ID: 38143738
[TBL] [Abstract][Full Text] [Related]
5. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation.
Bui AN; Hirner J; Singer SB; Eberly-Puleo A; Larocca C; Lian CG; LeBoeuf NR
Clin Exp Dermatol; 2021 Mar; 46(2):328-337. PubMed ID: 32939795
[TBL] [Abstract][Full Text] [Related]
6. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
7. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.
Zitouni NB; Arnault JP; Dadban A; Attencourt C; Lok CC; Chaby G
Melanoma Res; 2019 Apr; 29(2):212-215. PubMed ID: 30489484
[TBL] [Abstract][Full Text] [Related]
8. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
9. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L
JAMA Oncol; 2019 Jul; 5(7):1043-1047. PubMed ID: 31021392
[TBL] [Abstract][Full Text] [Related]
10. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
Thomas M; Armenti ST; Ayres MB; Demirci H
JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
[TBL] [Abstract][Full Text] [Related]
11. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
12. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
[TBL] [Abstract][Full Text] [Related]
13. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
14. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Andersson NW; Zachariae C; Simonsen AB
Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
[No Abstract] [Full Text] [Related]
15. Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
Figueredo Zamora E; Callen JP; Schadt CR
Lupus; 2021 Apr; 30(4):661-663. PubMed ID: 33349110
[TBL] [Abstract][Full Text] [Related]
16. [Subacute cutaneous lupus erythematosus induced by terbinafine].
Amitay-Layish I; Feuerman H; David M
Harefuah; 2006 Jul; 145(7):480-2, 552. PubMed ID: 16900733
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
18. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus.
Király Z; Szepesi Á; Sebestyén A; Kuroli E; Rencz F; Tóth B; Bokor L; Szakonyi J; Medvecz M; Hidvégi B
Pathol Oncol Res; 2022; 28():1610521. PubMed ID: 35979531
[TBL] [Abstract][Full Text] [Related]
20. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.
Ogawa-Momohara M; Muro Y; Goto K; Obuse C; Satoh M; Kono M; Akiyama M
J Dermatol; 2020 Jun; 47(6):e217-e219. PubMed ID: 32173880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
